N/A N=401 Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients
Abdominal Aortic Aneurysm · Iliac Aneurysm · Internal Iliac Aneurysm
Primary: Freedom From Aneurysm Rupture — 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=141 Iliac Artery Treatment With The Invatec Scuba™ Cobalt Chromium Stent (INTENSE)
Peripheral Artery Disease
Primary: Composite of Major Adverse Events (MAE) Defined as the Occurrence of In-hospital Myocardial Infarction (MI) or Target Segment Revascularization, Target Limb Loss, or…
N/A N=19 34mm Cuff Study for Endovascular Repair of Abdominal Aortic Aneurysms
Abdominal Aortic Aneurysm
Primary: Number of Participants With Proximal Type I Endoleak at Each Timepoint — 1; 0; 0; 0 Participants
N/A N=40 PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation Clinical Study
Aortoiliac Aneurysms · Iliac Aneurysms
Primary: Number of Patients With Freedom From Patency-related Intervention Defined as a Secondary Intervention to Treat a > 60 % Stenosis of the Internal Iliac Artery Associated…
N/A N=134 A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries.
Peripheral Arterial Disease
Primary: Composite of Major Adverse Events (MAEs) — 2.3 percentage of subjects experiencing MAE — p=<0.001
N/A N=194 Endurant Bifurcated and Aorto-Uni-Iliac (AUI) Stent Graft System
Abdominal Aortic Aneurysms
Primary: Primary Safety Endpoint (Freedom From MAEs Within 30 Days of Index Procedure) — 88.6; 96.0 percentage of participants
N/A N=64 Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis
Common Iliac Artery Aneurysms · Aorto-iliac Aneurysms
Primary: Freedom From Composite of the Following: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Conversion to Open…
Phase 3 N=153 Trial to Evaluate the Safety & Efficacy of the Omnilink Elite™ Peripheral Balloon-Expandable Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery
Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) — 5.4 percentage of participants
Phase 2 N=261 Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial
Aneurysm
Primary: Difference in Z-score for Rank of Maximum Transverse Diameter (MTD) Regressed on Z-score at Baseline to Assess Growth in Abdominal Aortic Aneurysm MTD Determined by CT…
Phase 4 N=881 Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA)
Aortic Aneurysm
Primary: All-cause Mortality — 146; 146 participants — p=0.81
N/A N=165 Atrium iCAST Iliac Stent Pivotal Study
Peripheral Vascular Disease
Primary: Percentage of ITT Population Experiencing Death Within 30 Days, Target Site Revascularization or Restenosis — 8.1 Percentage of subjects — p=0.005
N/A N=10 Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms
Thoracoabdominal Aortic Aneurysms
Primary: Freedom From Major Adverse Events (MAE) at Day 30 — 3; 4 Participants
Phase 3 N=151 Trial to Evaluate the Safety & Efficacy of the Absolute Pro™ Peripheral Self-Expanding Stent System in Subjects With Atherosclerotic de Novo or Restenotic Lesions in the Native Common Iliac Artery and/or Native External Iliac Artery.
Peripheral Vascular Disease
Primary: Major Adverse Event (MAE) Rate — 6.1 percentage of participants
N/A N=75 VISIBILITY™ Iliac Study
Peripheral Arterial Disease · Claudication
Primary: Major Adverse Event Rate at 9 Months — 4.0 percentage of participants
N/A N=10 GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms
Thoracoabdominal Aortic Aneurysm
Primary: Absence of the Following Procedural Safety Events: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Procedural Blood…
N/A N=925 Comparison of Outcomes of Complex Abdominal Aortic Aneurysm Treatment
Juxtarenal Aortic Aneurysm · Pararenal Aneurysm
Primary: Aortic Related Reintervention. — 44; 63 Participants
N/A N=44 Suprarenal Proximal Cuff Study for Treatment of Abdominal Aortic Aneurysm
Abdominal Aortic Aneurysm
Primary: Number of Subjects With Proximal Type I Endoleak — 2 Participants
N/A N=51 Impact of Grafts and Endografts for Abdominal Aneurysms on Arterial Stiffness.
Aortic Aneurysm, Abdominal
Primary: Aix@75 — 31.8; 32.5 percentage
N/A N=613 Immediate Management of the Patient With Rupture : Open Versus Endovascular Repair
Abdominal Aortic Aneurysm
Primary: Mortality — 111; 112; 133; 130 Participants
Phase 2 N=35 Study of the Large Diameter GORE EXCLUDER® AAA Endoprosthesis in Abdominal Aneurysms
Aortic Aneurysm, Abdominal
Primary: Time to First Major Adverse Event Experienced by Subjects From the Time of Treatment Through 1 Year — 84.0 days — p=0.003
N/A N=155 BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
Peripheral Artery Disease · Peripheral Vascular Disease · Arterial Occlusive Disease
Primary: Number of Participants With Device and/or Procedure-Related Death or Myocardial Infarction (MI) Through 30 Days, or Any Target Lesion Revascularization (TLR), Target…
Phase 4 N=259 GORE EXCLUDER® Endoprosthesis - Low Permeability in Treatment of Abdominal Aortic Aneurysms
Aortic Aneurysm, Abdominal
Primary: Number of Subjects With Aneurysm Volume Increase Greater Than 10% at 2 Years Post-procedure — 9; 31 participants — p=<0.001
N/A N=20 Evaluation of Contrast-Enhanced Ultrasound to Detect Endoleaks After Endovascular Aortic Aneurysm Repair
Endoleaks
Primary: Endoleak Detection — 9 Participants
N/A N=30 HORIZON CE Pivotal Study to Treat Abdominal Aortic Aneurysm
Infrarenal Abdominal Aortic Aneurysms · Aortoiliac Aneurysms
Primary: Safety Endpoint: Major Adverse Events (MAEs) — 30 Participants
N/A N=235 Preferences for Open Vs. Endovascular Repair for Abdominal Aortic Aneurysm
Abdominal Aortic Aneurysm
Primary: Veteran Preference for Repair Type — 25; 25; 95; 80 Participants
Phase 2 N=224 AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)
Abdominal Aortic Aneurysm
Primary: Change in the Growth Rate of Abdominal Aortic Aneurysm — 1.77; 1.81; 1.66 mm — p=0.78
N/A N=40 The Use and Reproducibility of Duplex Ultrasound to Provide Indices of Left Common Iliac Vein Diameter
May-Thurner Syndrome
Primary: Left Common Iliac Vein Diameter — 7.5; 7.7 Millimeters (mm)
N/A N=21 ARISE: Evaluation of the GORE® Ascending Stent Graft in the Treatment of DeBakey Type I/II Aortic Dissection
Aortic Dissection
Primary: All Cause Mortality at 30 Days Post-procedure — 3 Participants
N/A N=655 Aortoiliac Stenosis in Kidney Transplantation
Aorto-Iliac Arterial Stenosis · Peripheral Arterial Disease · Kidney Transplant Failure
Primary: Patient Survival — 322; 48; 6 Participants
N/A N=20 Endovascular Repair for the Descending Thoracic Aorta
Aorta Thoracic; Traumatic Rupture
Primary: Number of Participants With Major Adverse Events — 0 number of serious adverse events